Take­da nabs dengue vac­cine ap­proval in Eu­rope, as trav­el, cli­mate change con­tribute to rise in cas­es

Take­da’s dengue vac­cine Qden­ga is now ap­proved in the Eu­ro­pean Union, fol­low­ing its first ap­proval this sum­mer in In­done­sia. The big­ger ques­tion though, es­pe­cial­ly for Eu­rope, may be: is the vac­cine need­ed?

Take­da says yes. While dengue is not en­dem­ic to main­land Eu­rope, glob­al trav­el, in­creas­es in glob­al­iza­tion and cli­mate change lead­ing to a jump in out­breaks in non-en­dem­ic ar­eas mark a need for Qden­ga. It is the first dengue vac­cine that can be used with­out test­ing for pre­vi­ous in­fec­tion. Sanofi’s al­ready-ap­proved Deng­vax­ia does re­quire a pre-vac­ci­na­tion blood test.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER